- Home
- ASRT vs OPTN Comparison
ASRT vs OPTN Comparison
Compare ASRT & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASRT
- OPTN
- Stock Information
- Founded
- ASRT 1995
- OPTN 2010
- Country
- ASRT United States
- OPTN United States
- Employees
- ASRT N/A
- OPTN N/A
- Industry
- ASRT Biotechnology: Pharmaceutical Preparations
- OPTN Biotechnology: Pharmaceutical Preparations
- Sector
- ASRT Health Care
- OPTN Health Care
- Exchange
- ASRT Nasdaq
- OPTN Nasdaq
- Market Cap
- ASRT 85.1M
- OPTN 78.4M
- IPO Year
- ASRT 1997
- OPTN 2017
- Fundamental
- Price
- ASRT $0.83
- OPTN $6.33
- Analyst Decision
- ASRT Strong Buy
- OPTN Strong Buy
- Analyst Count
- ASRT 4
- OPTN 3
- Target Price
- ASRT $3.19
- OPTN $16.67
- AVG Volume (30 Days)
- ASRT 419.9K
- OPTN 50.2K
- Earning Date
- ASRT 03-10-2025
- OPTN 03-06-2025
- Dividend Yield
- ASRT N/A
- OPTN N/A
- EPS Growth
- ASRT N/A
- OPTN N/A
- EPS
- ASRT N/A
- OPTN N/A
- Revenue
- ASRT $125,763,000.00
- OPTN $75,672,000.00
- Revenue This Year
- ASRT N/A
- OPTN $13.42
- Revenue Next Year
- ASRT $1.84
- OPTN $38.54
- P/E Ratio
- ASRT N/A
- OPTN N/A
- Revenue Growth
- ASRT N/A
- OPTN 5.13
- 52 Week Low
- ASRT $0.73
- OPTN $4.82
- 52 Week High
- ASRT $1.80
- OPTN $31.50
- Technical
- Relative Strength Index (RSI)
- ASRT 45.42
- OPTN 38.92
- Support Level
- ASRT $0.78
- OPTN $5.71
- Resistance Level
- ASRT $0.85
- OPTN $6.35
- Average True Range (ATR)
- ASRT 0.03
- OPTN 0.55
- MACD
- ASRT 0.00
- OPTN -0.01
- Stochastic Oscillator
- ASRT 56.14
- OPTN 0.00
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.